I am in from 1996.
Axokine was modified CNTF (modified neurotrophic factor), and was THE WORSE FIASKO (and they withhold bad outcome data from p2, reported in journal article day after P3 fiasko)...
So, it was in house generated drug candidate witl all science available to REGN, at that time.
Today, with RGC they have even more data (markers, modality, causing genes, off-targets,...), so we will se how will they continue with program. Abs or siRNA? If they can do on its own, why should they share 50% of potential profit with others???
If liver is target organ, siRNA is ideal. For brain,.....not so sure! |
